Stay up-to-date on new clinical findings on Psoriasis. View the latest articles, case reports, supplements, CME activities, Podcast episodes and more!
J Drugs Dermatol. 2020;19(11):1101-1108. doi:10.36849/JDD.2020.5510
Clinical and economic comparisons of therapies for plaque psoriasis are regularly updated following each new development in the field. Among study comparators, the 308nm excimer laser is safe and delivers incremental clinical benefits with the potential for significant cost savings.
J Drugs Dermatol. 2020;19(9):874-880. doi:10.36849/JDD.2020.5020
Leon H. Kircik MD, Todd E. Schlesinger MD FAAD, Emil Tanghetti MD
In the treatment of moderate plaque psoriasis, Cal/BD foam plus apremilast provided more benefits than with apremilast alone. These improvements appeared to be lost when Cal/BD foam was withdrawn but recovered when Cal/BD foam was reinitiated.
J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5104R1
Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD
The relationship between the clearance of psoriasis and improved quality of life together with an increased uptake of cosmetic procedures has not been reported to date. A survey was conducted to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.
J Drugs Dermatol. 2020;19(8):741-746. doi:10.36849/JDD.2020.5116
Phoebe Rich MD, Orin Goldblum MD, Damon Disch PhD, Chen-Yen Lin PhDb, Joseph F. Merola MD, Boni Elewski MD
Presence of nail psoriasis in patients with plaque psoriasis may be an indicator of greater disease severity. Previously, patients with nail psoriasis have had delayed skin clearance after treatment compared to patients without nail psoriasis. This post-hoc analysis evaluated the efficacy of ixekizumab in clearance of plaque psoriasis in patients with and without nail psoriasis.
J Drugs Dermatol. 2020;19(8): doi:10.36849/JDD.2020.5337
Metabolic syndrome (MetS) is the most prevalent comorbidity in psoriasis and increases the risk of cardiovascular disease, diabetes, and mortality. Assessment of impacts of biologic therapies on cardiometabolic risk factors are relatively limited. This study evaluated the effect of tildrakizumab on cardiometabolic risk factors in patients with moderate to severe plaque psoriasis and stratified by MetS status.
J Drugs Dermatol. 2020;19(6): doi:10.36849/JDD.2020.4975
Leon H. Kircik MD
Newer biologics have introduced the possibility of higher and more complete clearance rates than previously possible. For many patients, PASI 90 and PASI 100 responses are realistic. Furthermore, higher levels of clearance, particularly total clearance, is associated with marked improvements in quality of life. Little data is available on the clinical benefits of higher clearance levels and how this might relate to improvements in other comorbidities. Is it time for dermatologists to strive for total clearance for our patients?
J Drugs Dermatol. 2020;19(4): doi:10.36849/JDD.2020.4910
Jerry Bagel, Bradley S. Stolshek, Yue Yang,b Gregory Kricorian, and Leon Kircik
Should patient-reported improvements in psoriasis and satisfaction with psoriasis treatment be considered along with traditional clinical measures when assessing patients?
J Drugs Dermatol. 2020;19(4): doi:10.36849/JDD.2020.5026
Mark Lebwohl MD, Jennifer Cather MD, April Armstrong MD MPH, Abby Van Voorhees MD, Abby Jacobson PA-C
This review discusses the efficacy and safety of brodalumab and other biologic therapies in patients with psoriasis who stop and restart treatment. These clinically relevant and important findings can help inform real-world treatment decisions.
J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.4690
William Abramovits MD, Joel Schlessinger MD
This narrative review discusses the efficacy and safety of systemic treatments for skin and joint manifestations in patients with psoriasis to provide dermatologists and rheumatologists with an updated summary of the benefits and risks of currently available treatments on several disease domains.
J Drugs Dermatol. 2019;18(8):804-813.
Andrew F. Alexis MD MPH, Marta Rendon MD, Jonathan I. Silverberg MD, David M. Pariser MD, et al.
Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for interleukin (IL)-4 and IL-13, is currently approved for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD).
J Drugs Dermatol. 2019;18(8):790-796.
Neal Bhatia MD,a Linda Stein Gold MD,b Leon H. Kircik MD,c Rhonda Schreiber MSd
A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations.
J Drugs Dermatol. 2019;18(8):776-788.
Lawrence J. Green MD,ª Paul S. Yamauchi MD PhD,b Leon H. Kircik MDc
Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling, and is associated with substantial physical, psychosocial, and economic health burdens. Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical management of patients with PsO by expanding treatment options to include multiple therapies with different mechanisms of action targeting cytokines, including tumor necrosis factor inhibitors (TNFis), interleukin (IL)-17A inhibitors, an IL-12/23 inhibitor, and IL-23 inhibitors.
J Drugs Dermatol. 2019;18(8):731-740.
Lauren Bonomo MD,a Brian J. Abittan MD,a Peter W. Hashim MD,a Chitra Karki MPH,c Marc Mason MS,c Mark Lebwohl MDa
Importance: There are increasing options for systemic combination therapy for psoriasis but a lack of literature around the characteristics of patients who are started on these regimens.
J Drugs Dermatol. 2018;17(3):247-250.
Kim A. Papp MD PhDa and Mark G. Lebwohl MDb
The advent of biologics has improved patient outcomes in the treatment of moderate-to-severe psoriasis. The time it takes for patients to see clinically meaningful improvement is an important aspect of disease management.
What questions should you be asking? What matters most when discussing therapeutic options? What is the best way to partner to ensure a long term relationship? If we could read minds this podcast would not be necessary but alas, it sorely is. Check it out!
We (and our patients) are fortunate to live during a time when we have many safe and effective options to treat a chronic inflammatory skin disease such as Psoriasis. We are reminded of this, nay inundated, with warm and fuzzy headlines in the lay dermatology press that humblebrag said efficacy. However, how does this translate to the real world, when the perfect, neat lines of clinical trials are blurred by practical issues such as access, patient and practitioner perception, and long term use and efficacy? In a JDD Podcast first, we had not one but two investigators share their work and first steps to evaluate just that.
I’m a biologic girl in a biologic world…or so I think myself and never say out loud when reviewing therapeutic options for moderate to severe psoriasis. We are so fortunate to have so many wonderful options, however certain clinical scenarios may limit our ability to capitalize on said armament mostly due to limited experience and data. Enter previous malignancy – in most phase 3 studies these patients are weeded out or the history of malignancy must be at least 5 years prior to entry. So what to do? Our colleagues at Tufts Medical Center asked this very question. Tune in to hear what Dr. David Rosmarin, Assistant Professor of Dermatology and Residency Program Director learned from performing a retrospective chart review and how his work and his experience guides his clinical decision making when managing psoriasis. Don’t flake (or is it scale?)….check it out.
In this edition of the JDD Podcast, Dr. Adam Friedman reviews phototherapy protocols and pearls with psoriasis expert Dr. Jashin Wu, Director of Research at Kaiser Permanente based on his study published in the August 2016 Journal of Drugs in Dermatology titled “Comparison of Phototherapy Guidelines for Psoriasis: A Critical Appraisal and Comprehensive Review.” Also tune in to hear how Dr. Wu counsels his psoriasis patients on psoriasis comorbidities and initiates, and manages them with phototherapy, topicals, and systemic immunosuppressants.
Dr. Jon Zippin, Assistant Attending Dermatologist and Assistant Professor of Dermatology at Weill Medical College of Cornell, elucidates the complexity of cAMP biology and the translational impact of PDE4 inhibition as it relates to chronic inflammatory skin diseases. Tune in to learn why targeting this pathway is clinically meaningful but also where more work is needed to improve outcomes.
Dr. Abrar Qureshi, Professor and Chair of Department of Dermatology at The Warren Alpert Medical School of Brown University, reviews his research to uncover the biological basis for many of the co-morbidities associated with, and risk factors for, psoriasis. Through this clear and clinically oriented presentation, the common pathophysiological threads are elucidated with a focus on identifying preventive strategies and therapeutic targets for current and future treatments.
© 2021 JDDonline - Journal of Drugs in Dermatology. Copyright © 2020 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
